SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 270 filers reported holding SAGE THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.78 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $56,207,000 | -23.4% | 400,648 | 0.0% | 0.39% | -22.2% |
| Q2 2019 | $73,353,000 | +15.1% | 400,648 | 0.0% | 0.50% | +11.8% |
| Q1 2019 | $63,723,000 | +35.8% | 400,648 | -18.2% | 0.45% | +13.6% |
| Q4 2018 | $46,920,000 | -32.8% | 489,822 | +0.0% | 0.40% | -20.6% |
| Q3 2018 | $69,781,000 | +3.3% | 489,801 | +13.5% | 0.50% | -6.0% |
| Q2 2018 | $67,577,000 | +2.8% | 431,723 | -4.3% | 0.53% | +4.1% |
| Q1 2018 | $65,756,000 | -11.5% | 451,097 | 0.0% | 0.51% | -35.4% |
| Q4 2017 | $74,300,000 | – | 451,097 | – | 0.79% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |